Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06563817 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

Name: The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage — clinical trial record (NCT06563817)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Saturn

StatusUnknown

PhasePhase 2

SponsorBeijing Tiantan Hospital

Started2024-08

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 21, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06

Trial status changed: Recruiting → Unknown

Beijing Tiantan Hospital

280 trials monitored

See 4 trials at risk

This prospective, multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of rapamycin in the treatment of communicating hydrocephalus secondary to intraventricular hemorrhage. Additionally, the underlying pathogenic mechanisms associated with this particular type of hydrocephalus will be investigated in greater depth, and populations that may benefit from rapamycin therapy will be identified.

Trial Details

NCT Number	NCT06563817
Lead Sponsor	Beijing Tiantan Hospital
Conditions	Communicating Hydrocephalus, Cerebral Intraventricular Hemorrhage, Secondary Normal Pressure Hydrocephalus, Post Hemorrhagic Hydrocephalus
Enrollment	53 participants
Start Date	2024-08
Primary Completion	2025-05 (estimated)
Study Completion	2025-07 (estimated)
Updated on ClinicalTrials.gov	2024-08-21